FDA commissioner commits to review of abortion pill

Washington Examiner

By Gabrielle M. Etzel

The Food and Drug Administration will conduct a review of the abortion pill mifepristone following intense pressure from Sen. Josh Hawley (R-MO) and anti-abortion advocates to review updated safety information for medication abortions. 

FDA Commissioner Marty Makary wrote in a letter to Hawley on Monday that he is “committed to conducting a review of mifepristone and working with professional career scientists at the agency who review this data.

Read more.

Previous
Previous

FDA Commissioner Marty Makary promises review of abortion pill’s safety

Next
Next

FDA commissioner pledges to investigate mifepristone